Joseph P. Lucia & Associates LLC Purchases New Stake in Haemonetics Corporation $HAE

Joseph P. Lucia & Associates LLC acquired a new position in shares of Haemonetics Corporation (NYSE:HAE) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 6,759 shares of the medical instruments supplier’s stock, valued at approximately $507,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Kemnay Advisory Services Inc. acquired a new position in shares of Haemonetics in the 4th quarter valued at about $26,000. Leonteq Securities AG acquired a new stake in shares of Haemonetics during the fourth quarter worth approximately $30,000. EverSource Wealth Advisors LLC grew its position in Haemonetics by 2,640.0% during the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 396 shares in the last quarter. Kestra Advisory Services LLC purchased a new position in Haemonetics during the fourth quarter valued at approximately $34,000. Finally, Kelleher Financial Advisors acquired a new position in Haemonetics in the 2nd quarter valued at approximately $38,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Trading Down 0.9%

Shares of NYSE:HAE opened at $89.98 on Tuesday. The company has a current ratio of 3.08, a quick ratio of 1.91 and a debt-to-equity ratio of 1.40. The stock has a market capitalization of $4.09 billion, a PE ratio of 44.11, a P/E/G ratio of 1.82 and a beta of 0.52. Haemonetics Corporation has a 1 year low of $47.31 and a 1 year high of $92.25. The firm has a fifty day moving average price of $79.39 and a 200 day moving average price of $67.33.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $1.08 by $0.06. The company had revenue of $339.38 million during the quarter, compared to analysts’ expectations of $327.86 million. Haemonetics had a return on equity of 27.55% and a net margin of 7.12%.The business’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.10 earnings per share. Analysts expect that Haemonetics Corporation will post 5.28 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on HAE. Barrington Research set a $95.00 target price on shares of Haemonetics in a research report on Friday, August 7th. JPMorgan Chase & Co. boosted their price target on shares of Haemonetics from $62.00 to $86.00 and gave the company a “neutral” rating in a report on Friday, August 7th. Raymond James Financial reiterated an “outperform” rating and set a $105.00 price objective on shares of Haemonetics in a report on Friday, August 7th. Citigroup boosted their target price on Haemonetics from $79.00 to $92.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Finally, Weiss Ratings raised Haemonetics from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Haemonetics presently has an average rating of “Moderate Buy” and an average target price of $90.89.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.